Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 9, 2015, Pages 1109-1121

  Talebian Yazdi, Mehrdad ^a   Loof, Nikki M ^a   Franken, Kees L M C ^a   Taube, Christian ^a   Oostendorp, Jaap ^a   Hiemstra, Pieter S ^a   Welters, Marij J P ^a   van der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; CT antigen; Lung cancer; XAGE 1b

Indexed keywords

CANCER TESTIS ANTIGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; PROTEIN XAGE 1B; UNCLASSIFIED DRUG; TUMOR ANTIGEN; XAGE1A PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER TISSUE; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CELLS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; ADENOCARCINOMA; AGED; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; BIOSYNTHESIS; COHORT ANALYSIS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; MOLECULAR GENETICS; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES;

EID: 84939565322     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1716-2     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380
3. van der Drift MA, Karim-Kos HE, Siesling S, Groen HJ, Wouters MW, Coebergh JW, de Vries E, Janssen-Heijnen ML (2012) Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 7:291–298
4. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719
5. Talebian Yazdi M, Keene KR, Hiemstra PS, van der Burg SH (2014) Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Rev Vaccines 13:87–116
6. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
8. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351–360
9. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625
10. Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M (2008) Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun 8:13
11. Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E (2005) XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 11:5496–5503
12. Davidson MR, Gazdar AF, Clarke BE (2013) The pivotal role of pathology in the management of lung cancer. J Thorac Dis 5:S463–S478
13. Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E (2012) Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer 131:E649–E658
14. de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70:2707–2717
15. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH (2008) Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 122:486–494
16. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107:11895–11899
17. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178–187
18. van der Burg SH, Ressing ME, Kwappenberg KM, De Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612–618
19. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449–5455
20. Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ, Welters MJ, van der Burg SH (2012) The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother 61:1953–1963
21. Heusinkveld M, Goedemans R, Briet RJ, Gelderblom H, Nortier JW, Gorter A, Smit VT, Langeveld AP, Jansen JC, van der Burg SH (2012) Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131:E74–E85
22. Aerts JG, Hegmans JP (2013) Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 73:2381–2388
23. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(−)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136:35–45
24. Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E (2007) Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 7:5
25. Reuschenbach M, von Knebel DM, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535–1544
26. Gallina G, Dolcetti L, Serafini P, De SC, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Investig 116:2777–2790
27. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, Shu S (2008) Tumor-induced CD11b+ Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 181:3291–3300
28. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689